Phaseline

Companies › Eupraxia Pharmaceuticals

Eupraxia Pharmaceuticals: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Gastroenterology; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
EP-104GI
Extended-release fluticasone propionate for gastrointestinal administration
NR3C1Phase 1Eosinophilic EsophagitisDec 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05608681EP-104GIPhase 1Eosinophilic EsophagitisGastroenterologyDec 2026

From the company's SEC filings

Cash of $81m on 2025-12-31; operating cash outflow about $29m a year; runway about 34 months at that burn, to Oct 2028

Private offerings reported to the SEC (Form D)

Specialist investors

Held by 9 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.

Targets

NR3C1 (1)

Companies with the same targets

Corcept Therapeutics Oticara Australia AstraZeneca Alimera Sciences Laboratorios Sophia S.A de C.V. Optinose US Santhera Pharmaceuticals Pop Test Oncology Pacira Pharmaceuticals Tiohundra

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.